| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbe1d40faa1ed62003e4b49d8b278688 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-587
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-587
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-29 |
| filingDate |
2004-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c2216d20d638790ba450a4715a3993a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94cc0387c82f5739d34e8eee08916215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14cf1ba48bf01ee7799226505565a2fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0bfe9d4f49aa8866bc6c8f6af7458c1 |
| publicationDate |
2005-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2534202-A1 |
| titleOfInvention |
Lipid glycerides for the treatment of neurodegenerative conditions involving demyelination |
| abstract |
A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of .gamma.-linolenic acid, dihomo-.gamma.-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-.beta.1 levels in the patient to therapeutic levels. |
| priorityDate |
2003-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |